NCT06700590 First-Line Intervention for PTSD - Intensive Treatment
| NCT ID | NCT06700590 |
| Status | Recruiting |
| Phase | — |
| Sponsor | ARQ National Psychotrauma Centre |
| Condition | PTSD - Post Traumatic Stress Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 186 participants |
| Start Date | 2024-11-21 |
| Primary Completion | 2028-04-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 186 participants in total. It began in 2024-11-21 with a primary completion date of 2028-04-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn if an intensive program can treat post-traumatic stress disorder (PTSD) in adults getting treatment for the first time, and whether it has lower societal costs. The main questions it aims to answer are: * Does an intensive program reduce PTSD symptoms? * How expensive is it on a societal level? Researchers will compare the intensive program to the standard weekly treatment to see if the intensive program works to treat PTSD. Participants will: * Get 5 days of intensive treatment in two weeks (with two preparatory and closing sessions), or weekly sessions * Get questionnaires and interviews 5 times in 9 months
Eligibility Criteria
Inclusion Criteria: * 18 years or older * PTSD diagnosis according to DSM-5 (CAPS-5); * PTSD diagnosis stemming from 2 or more potentially traumatic events (PTEs) * seeking first-time treatment for PTSD (or less than 8 sessions); * employed (working or on sick leave for less than two years) Exclusion Criteria: * Current psychotic disorder, severe alcohol or substance use disorder, high suicidal intent (MINI-S for DSM-5) and a concrete suicide plan, or severe aggressive behavior that poses danger for others * insufficient command of the Dutch language to be able to complete the assessments. This will be determined through clinical judgment at intake.
Contact & Investigator
Mirjam Mink-Nijdam, PhD
PRINCIPAL INVESTIGATOR
ARQ National Psychotrauma Center
Frequently Asked Questions
Who can join the NCT06700590 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying PTSD - Post Traumatic Stress Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06700590 currently recruiting?
Yes, NCT06700590 is actively recruiting participants. Contact the research team at m.mink@centrum45.nl for enrollment information.
Where is the NCT06700590 trial being conducted?
This trial is being conducted at Diemen, Netherlands, Haarlem, Netherlands, Groningen, Netherlands, Oegstgeest, Netherlands.
Who is sponsoring the NCT06700590 clinical trial?
NCT06700590 is sponsored by ARQ National Psychotrauma Centre. The principal investigator is Mirjam Mink-Nijdam, PhD at ARQ National Psychotrauma Center. The trial plans to enroll 186 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.